Nomenclature
Short Name:
MPSK1
Full Name:
Serine-threonine-protein kinase 16
Alias:
- EC 2.7.11.1
- HPSK
- TGF-beta stimulated factor 1
- TSF1
- MPSK
- PKL12
- Serine,threonine protein kinase 16
- STK16
Classification
Type:
Protein-serine/threonine kinase
Group:
Other
Family:
NAK
SubFamily:
NA
Specific Links
Structure
Mol. Mass (Da):
34656
# Amino Acids:
305
# mRNA Isoforms:
1
mRNA Isoforms:
34,656 Da (305 AA; O75716)
4D Structure:
NA
1D Structure:
3D Image (rendered using PV Viewer):
PDB ID
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|---|---|
| 20 | 292 | Pkinase |
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Myristoylated:
G2.
Palmitoylated:
C6,C8.
Serine phosphorylated:
S197-.
Threonine phosphorylated:
T185.
Tyrosine phosphorylated:
Y198-.
Ubiquitinated:
K102.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
77
1017
13
1101
20
262
12
284
3
44
1
0
30
402
48
668
46
605
14
585
2
33
37
13
22
285
19
515
100
1321
21
2222
22
287
10
248
7
99
47
69
7
89
14
42
47
622
86
656
5
63
14
17
6
76
9
125
4
54
12
95
5
70
10
32
2
33
100
27
3
46
9
39
4
53
55
105
29
388
58
414
6
74
11
54
4
53
12
28
6
78
2
46
7
92
12
90
4
56
12
30
55
722
29
983
5
72
17
28
4
50
10
43
5
61
9
67
7
89
14
74
51
679
18
461
43
573
17
562
0.9
12
17
9
69
905
26
743
5
71
13
21
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
99.7
99.7
100
99
99.7
99
-
-
92
-
-
96
95.7
97
96
-
-
-
94.1
97.7
94
95.4
97.4
95
-
-
-
-
-
-
68.2
82.3
68
69.8
84.9
68
-
-
66
-
-
-
39.1
58.8
42
40.6
63.2
-
-
-
-
39.7
64.6
-
-
-
-
-
-
-
-
-
38
-
-
39
27.5
45.9
36
-
-
39
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Binding Proteins
Examples of known interacting proteins
hiddentext
| No. | Name – UniProt ID |
|---|---|
| 1 | PAK1 - Q13153 |
| 2 | NCK1 - P16333 |
| 3 | RAF1 - P04049 |
| 4 | PXN - P49023 |
| 5 | SYN1 - P17600 |
| 6 | ARHGEF6 - Q15052 |
| 7 | GIT1 - Q9Y2X7 |
| 8 | PRMT5 - O14744 |
| 9 | PAK2 - Q13177 |
| 10 | NCK2 - O43639 |
| 11 | CDC42 - P60953 |
| 12 | RAC3 - P60763 |
| 13 | RAC2 - P15153 |
Regulation
Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Known Upstream Kinases
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
| Kinase Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
|---|
Known Downstream Substrates
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
| Substrate Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
|---|
| DRG1 | Q9Y295 | T101 | YEFTTLTTVPGVIRY | |
| MPSK1 (STK16) | O75716 | S197 | AAQRCTISYRAPELF | - |
| MPSK1 (STK16) | O75716 | T185 | EGSRQALTLQDWAAQ | |
| MPSK1 (STK16) | O75716 | Y198 | AQRCTISYRAPELFS | - |
| Sarcolipin | O00631 | T5 | MGINTRELFLNF___ |
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Inhibitors
For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
| Compound Name | KD, Ki or IC50 (nM) | PubChem ID | ChEMBL ID | PubMed ID |
|---|
Disease Linkage
General Disease Association:
Infectious disease
Specific Diseases (Non-cancerous):
Cryptococcosis; Diffuse Mesangial sclerosis (DMS)
Comments:
Cryptococcosis has a relation to the disorders of meningitis and systemic lupus erythematosus. Cryptococcosis is characterized by an infection with a fungus leading to the development of symptoms that include fatigue, fever, confusion, headache, blurred vision, and a dry cough. The disorder can take several weeks for the full display of symptoms, and it can affect the lung, the liver, and T cells. Diffuse Mesangial Sclerosis (DMS) is a rare disorder that has been related to the nephrotic and denysdrash syndromes. DMS may be characterized by proteinuria (protein in urine), hypoalbuminemia (low albumin levels in blood), and edema (accumulation of fluid in the interstitium under the skin). Myristoylation of MPSK1 can be inhibited with a G2A mutation, while palmitoylation can be lost with either a C6S or C8S mutation.
Gene Expression in Cancers:
TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in human T-cell prolymphocytic leukemia (%CFC= +120, p<0.004).
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.05 % in 24433 diverse cancer specimens. This rate is only -32 % lower than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.27 % in 603 endometrium cancers tested; 0.24 % in 1229 large intestine cancers tested; 0.18 % in 555 stomach cancers tested; 0.18 % in 548 urinary tract cancers tested; 0.12 % in 273 cervix cancers tested; 0.12 % in 1608 lung cancers tested; 0.11 % in 864 skin cancers tested; 0.07 % in 1512 liver cancers tested; 0.06 % in 558 thyroid cancers tested; 0.05 % in 710 oesophagus cancers tested; 0.04 % in 807 ovary cancers tested; 0.03 % in 1289 breast cancers tested; 0.03 % in 1253 kidney cancers tested.
Frequency of Mutated Sites:
Most frequent mutations with the number of reports indicated in brackets: R50Q (4).
Comments:
No deletions, insertions or complex mutations are noted on the COSMIC website.